1-9 of 9
Ronan J. Kelly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Ronan J. Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T. Catenacci, Hyun Cheol Chung, Zev A. Wainberg, Michael K. Gibson, Keun-Wook Lee, Johanna C. Bendell, Crystal S. Denlinger, Cheng Ean Chee, Takeshi Omori, Rom Leidner, Heinz-Josef Lenz, Yee Chao, Marlon C. Rebelatto, Philip Z. Brohawn, Peng He, Jennifer McDevitt, Siddharth Sheth, Judson M. Englert, Geoffrey Y. Ku
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (4): 846–854.
https://doi.org/10.1158/1078-0432.CCR-19-2443
Published: 14 February 2020
View article titled, Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Open the PDF for Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

Helena A. Yu, Alexander Spira, Leora Horn, Jared Weiss, Howard West, Giuseppe Giaccone, Tracey Evans, Ronan J. Kelly, Bhardwaj Desai, Andrew Krivoshik, Diarmuid Moran, Srinivasu Poondru, Fei Jie, Kouji Aoyama, Anne Keating, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (24): 7467–7473.
https://doi.org/10.1158/1078-0432.CCR-17-1447
Published: 14 December 2017
View article titled, A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations
Open the PDF for A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations in another window
Includes: Supplementary data
Journal Articles

New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer

Patrick M. Forde, Julie R. Brahmer, Ronan J. Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2244–2248.
https://doi.org/10.1158/1078-0432.CCR-13-2088
Published: 30 April 2014
View article titled, New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer
Open the PDF for New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer in another window
Journal Articles

New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice

Patrick M. Forde, Ronan J. Kelly, Julie R. Brahmer
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (5): 1067–1073.
https://doi.org/10.1158/1078-0432.CCR-13-0731
Published: 02 March 2014
View article titled, New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice
Open the PDF for New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice in another window
Journal Articles

A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors

Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummar, Eva Szabo, Mary Ann Yancey, Jiuping Ji, Baskar Mannargudi, Sukyung Woo, Shawn Spencer, William Douglas Figg, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2344–2351.
https://doi.org/10.1158/1078-0432.CCR-11-2425
Published: 16 April 2012
View article titled, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Open the PDF for A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Arun Rajan, Ronan J. Kelly, Jane B. Trepel, Yeong Sang Kim, Sylvia V. Alarcon, Shivaani Kummar, Martin Gutierrez, Sonja Crandon, Wadih M. Zein, Lokesh Jain, Baskar Mannargudi, William D. Figg, Brett E. Houk, Michael Shnaidman, Nicoletta Brega, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6831–6839.
https://doi.org/10.1158/1078-0432.CCR-11-0821
Published: 31 October 2011
View article titled, A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
Open the PDF for A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib

Ronan J. Kelly, Arun Rajan, Jeremy Force, Ariel Lopez-Chavez, Corrine Keen, Liang Cao, Yunkai Yu, Peter Choyke, Baris Turkbey, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, John J. Wright, Shivaani Kummar, Martin Gutierrez, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1190–1199.
https://doi.org/10.1158/1078-0432.CCR-10-2331
Published: 01 March 2011
View article titled, Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
Open the PDF for Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib in another window
Includes: Supplementary data
Journal Articles

A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

Ronan J. Kelly, Deborah Draper, Clara C. Chen, Robert W. Robey, William D. Figg, Richard L. Piekarz, Xiaohong Chen, Erin R. Gardner, Frank M. Balis, Aradhana M. Venkatesan, Seth M. Steinberg, Tito Fojo, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (3): 569–580.
https://doi.org/10.1158/1078-0432.CCR-10-1725
Published: 01 February 2011
View article titled, A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
Open the PDF for A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

Raffit Hassan, Steven J. Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan Weil, Daniel Laheru
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 6132–6138.
https://doi.org/10.1158/1078-0432.CCR-10-2275
Published: 16 December 2010
View article titled, Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Open the PDF for Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers in another window